Skip to main
GNFT
GNFT logo

GNFT Stock Forecast & Price Target

GNFT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Genfit SA has established a positive outlook driven by its strategic partnership with Ipsen, which reported €59 million in sales of Iqirvo for primary biliary cholangitis (PBC) and expects growth to accelerate in the U.S. Furthermore, Ipsen's positive Phase 2 data in primary sclerosing cholangitis (PSC) presents additional opportunities for milestone achievements, enhancing investor confidence. Lastly, Genfit's diversified pipeline, combined with its strategic alliances and proven execution history, reduces binary risk and supports a favorable assessment of its overall financial health.

Bears say

Genfit SA faces significant challenges that contribute to a negative outlook on its stock, primarily due to clinical and regulatory uncertainties surrounding its pipeline assets. The company's decision to halt the development of VS-01 for ACLF patients, prompted by serious adverse events, underscores the risks associated with its research endeavors. Additionally, the potential need for further financing to sustain pipeline expansion amidst competitive dynamics in the liver disease sector adds to the financial instability concerns facing the company.

GNFT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genfit - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genfit - ADR (GNFT) Forecast

Analysts have given GNFT a Strong Buy based on their latest research and market trends.

According to 1 analysts, GNFT has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genfit - ADR (GNFT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.